Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 5, 2008, Pages 529.e1-529.e10

  Morin Papunen, Laure ^a   Martikainen, Hannu ^a   McCarthy, Mark I ^e   Franks, Stephen ^f   Sovio, Ulla ^b,f   Hartikainen, Anna Liisa ^a   Ruokonen, Aimo ^a   Leinonen, Maija ^c   Laitinen, Jaana ^d   Järvelin, Marjo Riitta ^b,f   Pouta, Anneli ^a,c  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

C reactive protein (CRP); inflammatory parameter; insulin resistance; levonorgestrel releasing intrauterine device; metabolic outcome; oral contraceptive

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; DESOGESTREL; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; LIPID; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; INTRAUTERINE CONTRACEPTIVE DEVICE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METABOLISM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO;

EID: 54849413382     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.04.013     Document Type: Article

References (44)

1. Suvisaari J., and Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 54 (1996) 201-208
2. Graff-Iversen S., and Tonstad S. Use of progestogen-only contraceptives/ medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian survey. Contraception 66 (2002) 7-13
3. Crook D., Godsland I.F., and Wynn V. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins. Am J Obstet Gynecol 158 (1988) 1612-1620
4. Andre G. [Contraception at 40]. Gynecol Obstet Fertil 30 (2002) 616-624
5. Suwikrom S., and Jaisamrarn U. Comparison of the metabolic effects of oral contraceptive and nonhormonal contraceptive use in women over 40 years old. Contraception 71 (2005) 183-187
6. Nawrot T.S., Den Hond E., Fagard R.H., Hoppenbrouwers K., and Staessen J.A. Blood pressure, serum total cholesterol and contraceptive pill use in 17-year-old girls. Eur J Cardiovasc Prev Rehabil 10 (2003) 438-442
7. Wynn V., Adams P.W., Godsland I., et al. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1 (1979) 1045-1049
8. Williams M.J., Williams S.M., Milne B.J., Hancox R.J., and Poulton R. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes Relat Metab Disord 28 (2004) 998-1003
9. Friedman G.D., Tekawa I., Grimm R.H., Manolio T., Shannon S.G., and Sidney S. The leucocyte count: correlates and relationship to coronary risk factors: the CARDIA study. Int J Epidemiol 19 (1990) 889-893
10. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
11. Ford E.S. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care 22 (1999) 1971-1977
12. Godsland I.F., Crook D., Simpson R., et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323 (1990) 1375-1381
13. Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 29 (1995) 736-742
14. Chi I.C. The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Clin Obstet Gynecol 38 (1995) 872-889
15. Rantakallio P. The longitudinal study of the northern Finland birth cohort of 1966. Paediatr Perinat Epidemiol 2 (1988) 59-88
16. Jarvelin M.R., Sovio U., King V., et al. Early life factors and blood pressure at age 31 years in the 1966 northern Finland birth cohort. Hypertension 44 (2004) 838-846
17. Sugiuchi H., Uji Y., Okabe H., et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 41 (1995) 717-723
18. Wieland H., and Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lipid Res 24 (1983) 904-909
19. Levy J.C., Matthews D.R., and Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 (1998) 2191-2192
20. Biswas A., Viegas O.A., Roy A.C., Coeling Bennink H.J., Korver T., and Ratnam S.S. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids: a randomized comparative study: Implanon contraceptive implants: effects on carbohydrate metabolism. Contraception 68 (2003) 189-193
21. Nilsson C.G., Kostiainen E., and Ehnholm C. Serum lipids and high-density-lipoprotein cholesterol in women on long-term sustained low-dose IUD treatment with levonorgestrel. Int J Fertil 26 (1981) 135-137
22. Ahotupa M., Rauramo I., Vasankari T.J., Skouby S.O., and Hakonen T. Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin. Ann Med 36 (2004) 278-284
23. Barter P.J., and Rye K.A. High density lipoproteins and coronary heart disease. Atherosclerosis 121 (1996) 1-12
24. Das D.K. Cardioprotection with high-density lipoproteins: fact or fiction?. Circ Res 92 (2003) 258-260
25. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276 (1996) 882-888
26. Ulmer H., Kollerits B., Kelleher C., Diem G., and Concin H. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44 649 Austrian men and women. Eur J Cardiovasc Prev Rehabil 12 (2005) 433-441
27. Pouta A., Hartikainen A.L., Sovio U., et al. Manifestations of metabolic syndrome after hypertensive pregnancy. Hypertension 43 (2004) 825-831
28. Dunn N., Thorogood M., Faragher B., et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 318 (1999) 1579-1583
29. Graff-Iversen S., Hammar N., Thelle D.S., and Tonstad S. Use of oral contraceptives and mortality during 14 years' follow-up of Norwegian women. Scand J Public Health 34 (2006) 11-16
30. Heinemann L.A., Lewis M.A., Spitzer W.O., Thorogood M., Guggenmoos-Holzmann I., and Bruppacher R. Thromboembolic stroke in young women: a European case-control study on oral contraceptives; Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 57 (1998) 29-37
31. Tanis B.C., van den Bosch M.A., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 (2001) 1787-1793
32. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 349 (1997) 1202-1209
33. Baillargeon J.P., McClish D.K., Essah P.A., and Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90 (2005) 3863-3870
34. Chasan-Taber L., Willett W.C., Manson J.E., et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94 (1996) 483-489
35. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) trial investigators. Lancet 350 (1997) 757-764
36. Konje J.C., Otolorin E.O., and Ladipo O.A. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol 166 (1992) 15-19
37. Rogovskaya S., Rivera R., Grimes D.A., et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 105 (2005) 811-815
38. Chasan-Taber L., Willett W.C., Stampfer M.J., et al. A prospective study of oral contraceptives and NIDDM among US women. Diabetes Care 20 (1997) 330-335
39. Rimm E.B., Manson J.E., Stampfer M.J., et al. Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35 (1992) 967-972
40. Kim C., Siscovick D.S., Sidney S., Lewis C.E., Kiefe C.I., and Koepsell T.D. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA study: coronary artery risk development in young adults. Diabetes Care 25 (2002) 1027-1032
41. Lewis M.A., Heinemann L.A., Spitzer W.O., MacRae K.D., and Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 56 (1997) 129-140
42. Spitzer W.O., Faith J.M., and MacRae K.D. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 17 (2002) 2307-2314
43. Nieto F.J., Szklo M., Folsom A.R., Rock R., and Mercuri M. Leukocyte count correlates in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 136 (1992) 525-537
44. Koponen P., and Luoto R. Lisääntymisterveys suomessa: Terveys-2000 tutkimus (2004), National Public Health Institute, Helsinki, Finland 59